InfiCure Bio has started 2023 the way it ended 2022 – by welcoming new clients. During the autumn the Umeå-based company signed agreements with two international clients, before following up with an important collaboration agreement with the international CRO, InnoSer Laboratories.
“The collaboration with InnoSer increases the visibility of our NIF model. Considering the agreements we have recently signed, we’re looking forward with anticipation to the results this collaboration will generate”, says Sofia Mayans.
InfiCure Bio took important steps into the US market before the pandemic by signing several large agreements with companies in the US. The pandemic hit the American market hard, and InfiCure Bio quickly adapted its business model to the new situation. In 2022, the company began a more widespread marketing with a focus on additional markets in order to diversify the risks.
“Our strategy in 2022 was successful, with the majority of clients in the past year coming from outside the US. The company’s goal for 2023 is to increase the visibility of our NIF model by continuing our strategy to promote the model on multiple markets”, says Sofia Mayans.
The new agreement confirms that InfiCure’s model is still very much in demand in the US, and gives stability to the future of the Umeå company.
“Every agreement we sign gives an energy boost to the entire business. It is proof of the need for and the potential of our model”, says Sofia Mayans.
For further information, please contact:
Sofia Mayans, PhD, CEO, Inficure Bio
+46 70-366 46 66
sofia.mayans@inficurebio.com
About Inficure Bio
InfiCure Bio is a contract research organization located in Umeå, Sweden focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.
The company was founded in 2015 by Prof. Dan Holmberg and Dr. Sofia Mayans based on the extensive experience and expertise in immunology, inflammation, and fibrosis of its founders. InfiCure offers drug development services based on a panel of in vivo models for these indications including the proprietary NIF mouse model. The latter serves as a game-changing tool for pharma developers to validate new drugs more effective against liver fibrosis.
Homepage InfiCure Bio
